Clinical trial NCT01839526: A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Official title: A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Fabry Disease
Keywords: Fabry disease
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2013-04-25
Enrollment: 39
Sex: MALE
Minimum age (years): 5
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: No investigational drug will be administered in this study for the treatment of Fabry disease.

This will be a multicenter, multinational, non-treatment, cross-sectional study of young male patients with Fabry disease who have not yet initiated interventional treatment for this disease. The study will consist of a screening visit(s), a clinical investigation visit(s), and a follow-up phone contact.

The objectives of the study are:

* To document renal function and other Fabry disease manifestations across age in treatment-naïve, young male patients with Fabry disease.
* To provide a reference group for comparison with interventional clinical trials of Fabry disease.

The duration of each patient's participation in the study, inclusive of the screening visit and follow-up phone contact, will be approximately 12 weeks.

Detailed description: Patients who meet all eligibility criteria based on screening assessments will be scheduled to return to the clinic for assessments of renal function and other disease-related parameters, which may be scheduled over one or more clinical investigation visits. The clinical investigation visit(s) will be scheduled such that renal and cardiac assessments occur after the required medication washout (see exclusion criterion); other procedures may be performed either before or after the medication washout, at the discretion of the investigator.

Up to 100 patients will be enrolled in the study, including a minimum of 15 patients in each of the following age groups (based on age at screening): 5 to 11 years, 12 to 17 years, and 18 to 25 years.

All patients will be encouraged to enroll in the Fabry Registry (NCT00196742) for continued follow-up after completion of the study.

Eligibility criteria: Inclusion Criteria:

* The patient and/or their parent/legal guardian is willing and able to provide signed informed consent. If the patient is below the age of consent per local guidelines, he is willing to provide assent, if deemed able to do so.
* The patient must have a confirmed diagnosis of Fabry disease as documented by leukocyte α-galactosidase A (αGAL) of \<4 nmol/hr/mg leukocyte (preferred assay; results from a central laboratory). If the leukocyte αGAL activity assay is difficult to obtain, the patient may be enrolled based on documented plasma αGAL \<1.5 nmol/hr/mL (results from a central laboratory), with the agreement of the Genzyme Medical Monitor.

Exclusion Criteria:

* Patient has received prior treatment with enzyme replacement therapy (ERT) or oral pharmacological chaperone therapy for Fabry disease.
* Patient has received an investigational drug within 30 days of the screening visit.
* Patient is receiving any of the following medications and is clinically unable or unwilling to temporarily discontinue treatment with these medications for the indicated washout period prior to the renal function assessments until completion of these assessments:

  * Angiotensin converting enzyme inhibitors or angiotensin receptor blockers (6 week washout);
  * Non-steroidal anti-inflammatory drugs (3 day washout).
  * NOTE: Patients who are on chronic dialysis or have had a kidney transplant will not be required to discontinue the above medications because renal function assessments will not be performed in these patients.
* Patient has any contraindication mentioned in the labeling of iohexol. NOTE: patients with an eGFR \<30 mL/min/1.73m\^2 and patients who are on chronic dialysis or have had a kidney transplant may be enrolled irrespective of any contraindication to iohexol because iGFR will not be measured in these patients.
* Patient has any medical condition or extenuating circumstance which, in the opinion of the Investigator, could interfere with the patient's ability to complete all study procedures, or with the interpretation of study results (e.g., diabetes mellitus).
* The patient and/or their parent or legal guardian, in the opinion of the Investigator, is unable to adhere to the requirements of the study.

Primary outcomes:
measure: Glomerular Filtration Rate Estimated from Serum Creatinine (eGFR)
timeFrame: Day 1 to Week 8
measure: Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)
timeFrame: Day 1 to Week 8
measure: Protein Excretion Assessed from Three First-Morning Urine Voids
timeFrame: Day 1 to Week 12
Secondary outcomes:
measure: Cardiovascular Function
timeFrame: Day 1 to Week 8
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Investigational Site Number 840010
state: California
city: Decatur
country: United States
facility: Investigational Site Number 840006
state: Georgia
city: Cincinnati
country: United States
facility: Investigational Site Number 840003
state: Ohio
city: Salt Lake City
country: United States
facility: Investigational Site Number 840009
state: Utah
city: Fairfax
country: United States
facility: Investigational Site Number 840002
state: Virginia
city: Capital Federal
country: Argentina
facility: Investigational Site Number 032001
city: Wien
country: Austria
facility: Investigational Site Number 040001
city: Liège
country: Belgium
facility: Investigational Site Number 056001
city: Porto Alegre
country: Brazil
facility: Investigational Site Number 076001
city: Montreal
country: Canada
facility: Investigational Site Number 124001
city: Toronto
country: Canada
facility: Investigational Site Number 124004
city: Vaasa
country: Finland
facility: Investigational Site Number 246002
city: Bron Cedex
country: France
facility: Investigational Site Number 250002
city: Garches
country: France
facility: Investigational Site Number 250001
city: Pécs
country: Hungary
facility: Investigational Site Number 348001
city: Bergen
country: Norway
facility: Investigational Site Number 578001
city: Warszawa
country: Poland
facility: Investigational Site Number 616001
city: Badalona
country: Spain
facility: Investigational Site Number 724001
city: Girona
country: Spain
facility: Investigational Site Number 724002
city: Taipai
country: Taiwan
facility: Investigational Site Number 158001
city: London
country: United Kingdom
facility: Investigational Site Number 826004
city: London
country: United Kingdom
facility: Investigational Site Number 826002
Study officials:
affiliation: Genzyme, a Sanofi Company
name: Medical Monitor
role: STUDY_DIRECTOR
References: